Kenvue Inc. (NYSE:KVUE) Receives $21.44 Consensus Target Price from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have been assigned a consensus rating of “Hold” from the ten research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $21.44.

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft increased their price objective on Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Kenvue in a research report on Wednesday, August 7th. UBS Group lifted their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. increased their target price on shares of Kenvue from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Finally, Citigroup dropped their price target on Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $23.18 on Monday. Kenvue has a 12 month low of $17.67 and a 12 month high of $23.55. The firm has a market capitalization of $44.39 billion, a P/E ratio of 29.72, a P/E/G ratio of 2.92 and a beta of 1.40. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.99 and a quick ratio of 0.68. The company’s fifty day moving average price is $20.73 and its 200 day moving average price is $19.91.

Kenvue (NYSE:KVUE) last posted its earnings results on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. The business had revenue of $4 billion for the quarter, compared to analysts’ expectations of $3.93 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. The business’s revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.32 earnings per share. As a group, sell-side analysts predict that Kenvue will post 1.08 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 28th. Stockholders of record on Wednesday, August 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.54%. This is an increase from Kenvue’s previous quarterly dividend of $0.20. The ex-dividend date was Wednesday, August 14th. Kenvue’s dividend payout ratio is 105.13%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Marathon Capital Management grew its stake in shares of Kenvue by 0.3% during the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares during the period. Manchester Capital Management LLC increased its holdings in Kenvue by 80.8% in the first quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock valued at $25,000 after buying an additional 530 shares in the last quarter. Poehling Capital Management INC. lifted its position in shares of Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company’s stock valued at $1,908,000 after acquiring an additional 547 shares during the period. Pathway Financial Advisers LLC boosted its stake in shares of Kenvue by 12.0% during the 2nd quarter. Pathway Financial Advisers LLC now owns 5,131 shares of the company’s stock worth $93,000 after acquiring an additional 549 shares in the last quarter. Finally, Tradition Wealth Management LLC grew its holdings in shares of Kenvue by 2.8% in the 4th quarter. Tradition Wealth Management LLC now owns 21,278 shares of the company’s stock worth $458,000 after acquiring an additional 575 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.